Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06147791
Other study ID # 833.300
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2023
Est. completion date October 1, 2033

Study information

Verified date November 2023
Source Azienda Ospedaliera Città della Salute e della Scienza di Torino
Contact Falcone Mr Marco, Physician
Phone 0116336594
Email marco.falcone@unito.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this prospective randomized study is to demonstrate if the use of an external scrotal drainage in penile prosthetic surgery can reduce the risk of post-operative complications without increase the risk of infections.


Description:

After being informed about the study, all patients give writted informed consent. After that they will be randomized in two groups (A with drainage, B without drainage) using a random sequence generator. Then the patient will undergo the implantation of a three-component penile prosthesis following peri antibiotic prophylaxis with cephalosporins and aminoglycosides, the antibiotic prophylaxis will be continued on the first post-operative day surgery with a cephalosporin. In the group A it will be positioned at the scrotal level (using surgical access or using a second incision) an external drainage (10 Ch in aspiration) for 24 hours. The drainage will be removed on the first post-operative day. The degree of the hematoma will be determined using a 5-point Likert scales already approved in previous cases. Subsequently patients will carry out periodic check-ups at 7, 15 and 30 days after the operation to evaluate the appearance of hematomas and surgical site infection. After that, they will carry out check-ups every month for the first 3 months, then every 3 months for the first year and finally annually up to the fifth year after the intervention. During the clinical check-ups, it will also be defined the time of use of the penile prosthesis.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date October 1, 2033
Est. primary completion date October 1, 2028
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Written informed consent signed voluntarily according to the rules of good clinical practice (Declaration of Helsinki) and national regulations (Appendix B). - Genetically male patient. - Age = 18 years. - Patient suffering from ED of variable and/or multifactorial etiology. - Patient suffering from ED not responsive to iPDE-5. - Patient suffering from unresponsive or non-tolerant ED Exclusion Criteria: - Absence of signed written informed consent (Appendix B). - Age <18 years. - Genetically female patients. - Patient with active peno-scrotal infection. - Patient with active systemic infection. - Immunosuppressed patient. - Patient with haematological pathologies that may cause an increased risk of bleeding. - Patients suffering from Peyronie's Disease who must undergo simultaneous plaque surgery. - Any condition or situation that, in the opinion of the investigator, places the patient at significant risk, may confound the results of the study, or significantly interfere with the patient's participation in the study. - The patient declares that it will be impossible for him to participate in follow-up consultations.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
External scrotal drainage
Application of external scrotal drainage during three-component penile prosthesis placement

Locations

Country Name City State
Italy SCDU Urologia Torino
Italy A.O.U. Città della Salute e della Scienza di Torino Turin

Sponsors (1)

Lead Sponsor Collaborator
Azienda Ospedaliera Città della Salute e della Scienza di Torino

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post-operative infectious episodes Define the number of post-operative infectious episodes in the two study arms. One month
Secondary Post-surgical hematoma Define the risk of post-surgical hematoma formation in the two study arms. One month
Secondary Volume of drained material Evaluate the volume of drained material in the group with external drainage. 24 hour
Secondary Manipulation of the activation pump Define the time elapsed between surgery and subsequent manipulation of the activation pump in the two study arms, usually 2 weeks. Up to 12 weeks
Secondary Activation of the device Define the time elapsed between the surgical intervention and the subsequent activation of the device in the two study arms, usually 3 weeks. Up to 12 weeks
Secondary Use of the penile prosthesis Define the time elapsed between surgery and the use of the penile prosthesis for sexual activity in the two study arms, usually 4 weeks after surgery. Up to 12 weeks
Secondary Effectiveness of external drainage in subgroups Compare, through a sub-analysis, the effectiveness of external drainage in different patient populations: heart patients, diabetics, duration of surgery.
We will test the effectiveness of external drainage in these soubgroups using the IIEF questionnaires.
Up to 12 months
Secondary Effectiveness of external drainage in subgroups Compare, through a sub-analysis, the effectiveness of external drainage in different patient populations: heart patients, diabetics, duration of surgery.
We will test the effectiveness of external drainage in these soubgroups using the SSIPI questionnaires.
Up to 12 months
Secondary Effectiveness of external drainage in subgroups Compare, through a sub-analysis, the effectiveness of external drainage in different patient populations: heart patients, diabetics, duration of surgery.
We will test the effectiveness of external drainage in these soubgroups using the QoLPSS questionnaires.
Up to 12 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05366504 - LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment Phase 2/Phase 3
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Recruiting NCT02573805 - the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males N/A
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Recruiting NCT02225548 - Sagene 2014 - Parkinson's Disease and Erectile Dysfunction Phase 4
Completed NCT02587988 - Trial to Evaluate the Efficacy and Safety of HCP1302 Phase 3
Completed NCT01937871 - A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED) Phase 3
Completed NCT02945462 - Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED) Phase 1
Completed NCT01698684 - Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction Phase 4
Not yet recruiting NCT01321489 - A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies Phase 3
Completed NCT01230541 - Effect of Udenafil on Spermatogenesis Phase 1
Terminated NCT01262833 - Pudendal Assessment in Erectile Dysfunction N/A
Completed NCT02226237 - Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy N/A
Completed NCT01037244 - Treatment of Erectile Dysfunction I Phase 3
Completed NCT01037218 - Treatment of Erectile Dysfunction II Phase 3
Recruiting NCT00313898 - Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males Phase 4
Completed NCT00663728 - Assessment of Duration of Erection With Vardenafil 10 mg Phase 4
Completed NCT00667979 - Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse Phase 4
Completed NCT00421083 - Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury Phase 3